A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (10
mg) relative to the original OxyContin® (OXY) formulation (10 mg) in the fed state.